Form 4: Emergent BioSolutions EVP Sells Shares Under 10b5-1 Plan

Coleen Glessner, EVP of Quality & Ethics at Emergent BioSolutions Inc., sold 30,608 shares of common stock for $10.00 per share on October 7, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Coleen Glessner, EVP, Quality & Ethics, and CPL at Emergent BioSolutions Inc. (EBS), reported a sale of common stock.
• The transaction occurred on October 7, 2025.
• A total of 30,608 shares of common stock were disposed of.
• The shares were sold at a price of $10.00 per share.
• Following this transaction, Ms. Glessner directly beneficially owns 144,319 shares of common stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) trading plan adopted on December 2, 2024.
• The Form 4 filing was submitted late due to an inadvertent administrative error.

Sentiment

Score: 4

Explanation: The sale by an executive, even under a 10b5-1 plan, can be perceived negatively by the market. The late filing due to an administrative error adds a minor negative administrative note, though the company's commitment to report it in the proxy statement mitigates some concern.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information.

Negatives

• An executive officer sold a significant number of shares (30,608 shares).
• The Form 4 was filed late due to an inadvertent administrative error.

Risks

• Administrative error leading to late SEC filing, which the company will report in its next proxy statement.
• Potential for negative market perception due to insider selling, despite the 10b5-1 plan.

Future Outlook

The company stated it will report all late Form 4 filings in its next proxy statement, indicating a commitment to transparency regarding administrative oversights.

Management Comments

• All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on December 2, 2024 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
• All shares sold at an exact price of $10.00.
• This Form 4 was filed late due to an inadvertent administrative error. The Company will report all late Form 4s in its next proxy statement.

Industry Context

Insider sales, particularly by high-ranking executives, are common in the biotechnology and pharmaceutical sectors as part of personal financial planning or diversification, often facilitated by 10b5-1 plans to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders may interpret the executive's sale as a signal, potentially impacting investor confidence, although the 10b5-1 plan suggests a pre-planned personal financial move rather than a reaction to new company-specific information.

Next Steps

• The Company will report all late Form 4s in its next proxy statement.

Key Dates

Recommendation

The sale by an EVP, while a notable insider transaction, was executed under a pre-arranged 10b5-1 trading plan, which typically indicates a planned diversification or liquidity event rather than a reaction to new, adverse company developments. The late filing is an administrative oversight that the company has acknowledged and committed to addressing in its proxy statement. Without additional context on broader insider activity, company fundamentals, or significant market shifts, this single transaction does not warrant a change from a 'hold' position.

Keywords

Emergent BioSolutions, EBS, Insider Trading, Form 4, Coleen Glessner, Stock Sale, 10b5-1 Plan, Executive Compensation, Biotechnology, Pharmaceuticals